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Abstract
More than 80% of multiple sclerosis (MS) patients suffer from fatigue. Despite this, there are few therapeutic options
and evidence-based pharmacological treatments are lacking. The associated societal burden is substantial (MS fatigue
is a major reason for part-time employment or early retirement), and at least one out of four MS patients view fatigue
as the most burdensome symptom of their disease. The mechanisms underlying MS-related fatigue are poorly
understood, and objective criteria for distinguishing and evaluating levels of fatigue and tiredness have not yet been
developed. A further complication is that both symptoms may also be unspecific indicators of many other diseases
(including depression, sleep disorders, anemia, renal failure, liver diseases, chronic obstructive pulmonary disease, drug
side effects, recent MS relapses, infections, nocturia, cancer, thyroid hypofunction, lack of physical exercise). This paper
reviews current treatment options of MS-related fatigue in order to establish an individualized therapeutic strategy that
factors in existing comorbid disorders. To ensure that such a strategy can also be easily and widely implemented, a
comprehensive approach is needed, which ideally takes into account all other possible causes and which is moreover
cost efficient. Using a diagnostic interview, depressive disorders, sleep disorders and side effects of the medication
should be identified and addressed. All MS patients suffering from fatigue should fill out the Modified Fatigue Impact
Scale, Epworth Sleepiness Scale, the Beck Depression Inventory (or a similar depression scale), and the Pittsburgh Sleep
Quality Index (or the Insomnia Severity Index). In some patients, polygraphic or polysomnographic investigations
should be performed. The treatment of underlying sleep disorders, drug therapy with alfacalcidol or fampridine,
exercise therapy, and cognitive behavioral therapy-based interventions may be effective against MS-related
fatigue. The objectives of this article are to identify the reasons for fatigue in patients suffering from multiple
sclerosis and to introduce individually tailored treatment approaches. Moreover, this paper focuses on current
knowledge about MS-related fatigue in relation to brain atrophy and lesions, cognition, disease course, and other
findings in an attempt to identify future research directions.
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Background
Multiple sclerosis (MS) is a chronic inflammatory and
neurodegenerative autoimmune disease of the central ner-
vous system with multifactorial etiopathogenesis, which
predominantly affects young adults and women [1–3]. At
least one out of four MS patients views fatigue as the most
burdensome symptom of their illness, and the majority of
MS patients (more than 80%) suffer from fatigue [4]. Fa-
tigue may occur at any stage of the disease and can even
precede MS onset by several years [5]. Fatigue is a major
reason for early retirement, reduced employment, and
poor quality of life in people with MS [6–8].
The 1998 clinical practice guidelines recommended by
the Consortium of Multiple Sclerosis Centers (the so-
called MS Council, a consensus group of 22 North
American associations including the American Academy
of Neurology, the Consortium of Multiple Sclerosis
Centers, and the US National Multiple Sclerosis Society)
have defined MS-related fatigue as “a subjective lack of
physical and/or mental energy that is perceived by the
individual or caregiver to interfere with usual and de-
sired activities” [9]. According to this definition, fatigue
not only is a symptom but also has a major impact on
daily activities.
The precise mechanisms of MS-related fatigue are not
known, and several non-MS-related possible reasons for
fatigue and tiredness should be taken into account [2].
This paper reviews current data about MS-related fatigue
and neuroanatomical findings, cognitive impairment,
depression, disease-modifying therapies, and disease
course, on the one hand, and major confounders and
other (symptomatic) reasons for fatigue and tiredness,
on the other. Furthermore, the aim of this paper is to
provide physicians with a clinically applicable treat-
ment algorithm for MS-related fatigue. This review is
an updated and extended version of a recently pub-
lished article in German [10].
Assessment and diagnostics
Fatigue questionnaires
Several scales are available for measuring fatigue. The
first published fatigue scale was the unidimensional
Fatigue Severity Scale (FSS) in 1989 identifying the
existence and severity of fatigue [11]. Nine years later,
the MS Council recommended the multidimensional
Modified Fatigue Impact Scale (MFIS, 21 items),
measuring the impact of fatigue on cognitive func-
tioning and psychosocial as well as physical domains
[9]. The MFIS is an abbreviated version of the Fatigue
Impact Scale (FIS, 40 items) [12]. The FIS itself is a
more concise version of the 138 items listed by the “Mul-
tiple Sclerosis Quality-of-Life Inventory” (MSQLI) [13].
The FSS and the MFIS are not specific for MS-related fa-
tigue and show an overlap with depression and tiredness
due to sleep disorders [2, 11, 14]. Most studies used a
MFIS cutoff of 38 or 45 [15–17]. For details about the psy-
chometric data and validation of these questionnaires,
please see a recent review [2]. Finally, in 2009, the Fatigue
Scale for Motor and Cognitive Functions (FSMC) was in-
troduced [18].
MS fatigue and tiredness
Unlike sleepiness, mental (cognitive) fatigue and tired-
ness cannot be measured by polysomnography or elec-
troencephalography. Both can only be assessed indirectly
by neuropsychological investigations or vigorimeter test-
ing and handgrip performance [19].
Moreover, outside the specific context of MS, patients
suffering from sleep disorders who were consecutively
admitted to a sleep laboratory also showed high mean
MFIS values (untreated sleep apnea 32.5, periodic limb
movement disorder and restless legs syndrome 44.1, in-
somnia 33.5) [14]. The same was found for the FSS.
Compared with men and older patients, the MFIS and
FSS values were higher in women and in young patients.
This is of particular importance because young women
are typically overrepresented among MS patients.
In summary, no objective diagnostic criteria for distin-
guishing between MS- and non-MS-related tiredness
and fatigue exist. For this reason, other possible under-
lying causes of these symptoms have to be taken into
account.
MS-related fatigue versus sleepiness
MS-related fatigue and tiredness can clinically and ob-
jectively (by polysomnography and by the multiple sleep
latency test) be distinguished from sleepiness: Sleepiness
is defined by the propensity to fall asleep, often associ-
ated with an effort to avoid sleeping and is generally
caused by sleep disorders or by disturbances of the cir-
cadian rhythm [20, 21]. Therefore, screening for sleepi-
ness is very important in fatigued MS patients because
sleepiness is an important indicator for an underlying
sleep disorder [22, 23]. All fatigued patients should be
asked about sleepiness and fill in the Epworth Sleepiness
Scale (ESS). ESS values equal or greater than 10 indicate
excessive daytime sleepiness (EDS), and in this case,
patients should undergo polygraphy or polysomnogra-
phy [20].
However, in sleep disorders outside the context of
MS (in patients suffering from sleep disorders in the
general population who are admitted to a sleep labora-
tory), fatigue and sleepiness can occur independently or
simultaneously [24, 25]. The majority of them, almost
two thirds, report pathological fatigue without sleepi-
ness and almost one fifth fatigue and sleepiness. How-
ever, only a small number of patients with sleep
disorders (4%) suffer from sleepiness and do not feel
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fatigued (13% experienced neither fatigue nor sleepi-
ness) [25]. This means that it is very important to ask
MS patients about sleepiness, because sleepiness indicates
sleep problems and is an argument against MS-related fa-
tigue. However, these data show clearly that the lack of
sleepiness is not an argument against the presence of sleep
disorders: although sleepiness is more specific to an
underlying sleep disorder, fatigue remains the most com-
mon symptom of an underlying sleep disorder.
Fatigability and motor fatigue
We have to distinguish between sustained perceived fa-
tigue from load-dependent fatigability, on the one hand,
and impaired performance during a motor task and an
increased subjective experience of fatigue, on the other
[26]. Studies investigating load-dependent abnormal
fatigability, maximal strength, subjective fatigue, and
surface electromyography have shown a correlation be-
tween the changes in subjective fatigue and changes in
strength in people with MS—but not a relationship be-
tween subjective fatigue and the changes in the amplitude
of the electromyography. In other words, repetitive
motor tasks did not lead to a performance decline, but
fatigue feelings clearly increased during a repetitive
motor task [27]. The increased experience of fatigue
can be confounded by depression, and the objective
signs of fatigability are normally not assessed in clinical
praxis [19, 26, 28, 29]. Moreover, most published stud-
ies investigating MS-related fatigue assessed fatigue by
questionnaires, as opposed to objective investigations.
As mentioned above, the MFIS can be divided into
three subscales. The nine items of the “physical subscale”
measure motor fatigue. Patients can perceive physical
(motor) fatigue and mental (cognitive) fatigue simultan-
eously. An exact definition of motor fatigue is lacking,
but usually, motor fatigue is defined as a reduction in
maximal walking distance that cannot be explained by
the degree of paresis, ataxia, or spasticity [30].
Gait recording using a camera system and infrared
markers attached to the patient’s body and connected by
cable to a unit worn on a belt allows the objective assess-
ment of gait abnormalities after physical exertion and ex-
haustion. Therefore, the changes in gait parameters after
physical exertion can be regarded as one possibility to dis-
tinguish objectively motor fatigue from fatigue by depres-
sion or normal tiredness—a clear diagnostic statement
which, unfortunately, is lacking in the domain of cognitive
fatigue and tiredness [30].
Studies using functional magnetic resonance imaging
(fMRI) to test whether a different pattern of movement-
associated cortical and subcortical activation might con-
tribute to the development of fatigue in patients with
MS showed more significant activation of the contralat-
eral primary somatomotor cortex, the ipsilateral rolandic
operculum, and the thalamus, indicating impaired inter-
action between functionally related cortical and subcor-
tical areas in motor fatigue [31].
Primary versus secondary fatigue
Studies investigating MS-related fatigue distinguish be-
tween primary and secondary fatigue. Stankoff et al. state
that “in some cases, fatigue may be secondary to depres-
sion, cognitive dysfunction, poor sleep, or motor impair-
ment. Nevertheless, for many patients, fatigue exists
independently of motor weakness, cognitive, or mood dis-
orders: this primary fatigue….” [16]. Yet the differentiation
between primary fatigue (due to MS) and secondary fa-
tigue (due to other diseases, e.g., depression and sleep dis-
orders) is not always clear. The prevalence of restless legs
syndrome (RLS) is four times higher in MS patients than
in the general population and may be related to spinal
cord damage [32, 33]. So, are fatigued MS patients with
RLS due to spinal cord lesions suffering from primary or
secondary fatigue? What exactly is primary fatigue?
Discrimination between fatigue, motor fatigue, tiredness,
and sleepiness
Figure 1 displays schematically the relationship between
primary and secondary fatigue, tiredness, motor fatigue,
and sleepiness. Whereas motor fatigue (as one aspect
and a specific manifestation of primary fatigue) can be
measured objectively by gait recording, mental (cogni-
tive) primary fatigue cannot be distinguished objectively
from tiredness and secondary fatigue. Sleepiness is com-
pletely different from primary or secondary fatigue or
tiredness and can be measured objectively by multiple
sleep latency test (MSLT) [20].
Clinical correlates and biological mechanisms
Disease course and disability
Patients with higher disability (according to the Expanded
Disability Status Scale (EDSS)) [34] suffer from fatigue
more frequently [35, 36], and older MS patients as well as
those with longer disease duration tend to have more fa-
tigue [36, 37]. Findings vary regarding disease course:
Whereas some studies found fatigue to be more prevalent
in progressive MS [17, 36, 37], other studies were not able
to confirm this relationship [35, 38]. A recent study identi-
fied fatigue as an independent predictor of a subsequent
MS diagnosis in a cohort of over 100 patients with a clin-
ically isolated syndrome [39].
Cognitive function, neuropsychological deficits,
depression, and fatigue
MS is a complex neurological illness that is often accom-
panied by neuropsychiatric symptoms. Indeed, major de-
pression is the most common comorbidity in MS [40].
In addition, more than 60% of MS patients experience
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cognitive impairment during the course of their illness,
with information processing, executive functioning, at-
tention, and memory most commonly affected [41–47].
Rather than broad cognitive impairment, MS is better
characterized by relatively specific, domain-dependent
deficits [48]. However, accurate neuropsychological as-
sessment is complicated in MS, because fatigue and de-
pression themselves may have detrimental effects on
cognitive function. For instance, poor performance could
be confounded by comorbid depressive symptomatology
or fatigue, especially as cognitive complaints can be sub-
tle. For example, the Paced Auditory Serial Addition
Test (PASAT), often used as a primary tool to assess
working memory and processing speed [49], may be vul-
nerable in repeated neuropsychological assessments to
practice effects that obscure the impact of fatigue. More
specifically, one study found that while PASAT perform-
ance increased with each trial, so did fatigue [50].
Similarly, while subjective fatigue has been associated
with reduced cognitive performance [4, 51, 52], this rela-
tionship was not confirmed in other studies [12, 53–56],
indicating that the interplay between cognitive dys-
function and fatigue is more complex than could be
expected from direct adverse effects of fatigue on
quality of life or disability. Indeed, it has been sug-
gested that while cognitive exhaustion may heighten
levels of fatigue, severe fatigue does not necessarily
reduce cognitive performance [52].
In line with the well-known effects of depression in
healthy subjects, and despite earlier negative findings
(e.g., [57]), a review has corroborated the association be-
tween depression and cognitive function in MS [58].
More specifically, it was shown that high levels of de-
pression mainly affect cognitive functions that are re-
source intensive, such as attention, working memory, or
planning [59–61]. Notably, the adverse effects of depres-
sion may be mediated by reductions in processing speed
[62], which have also been observed in non-depressed
patients with MS [63–65].
An international consortium of MS experts has rec-
ommended a battery of tests known as the “Minimal
Assessment of Cognitive Function in Multiple Sclerosis”
(MACFIMS) for routine monitoring of MS-associated
cognitive impairment [66]. The MACFIMS takes
roughly 90 min to administer and assesses language
(Controlled Oral Word Association Test), spatial pro-
cessing (Judgment of Line Orientation Test), learning and
memory (California Verbal Learning Test (CVLT)), Brief
Visuospatial Memory Test (BVMT), processing speed,
and working memory (Symbol Digit Modalities Test,
PASAT) as well as executive function (Delis-Kaplan Ex-
ecutive Function System Sorting Test) [66]. Alternatively,
Fig. 1 Distinction between primary fatigue, secondary fatigue, and sleepiness. This figure displays possibilities for distinguishing the primary
fatigue from secondary fatigue, tiredness, and sleepiness. Whereas primary motor fatigue can be distinguished objectively from tiredness and
secondary fatigue by gait recording, primary cognitive fatigue indeed cannot be distinguished objectively from tiredness and secondary fatigue.
Sleepiness can clearly be distinguished from primary and secondary fatigue and motor fatigue and tiredness—as sleepiness can be measured
objectively by the multiple sleep latency test
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an abbreviated combination is available that takes approxi-
mately 15 min to complete (Brief International Cognitive
Assessment for Multiple Sclerosis (BICAMS)) and in-
cludes the SDMT, CVLT-II (first five recall trials only),
and BVMT-R (first three recall trials only) [67].
In summary, assessment of neuropsychological impair-
ment in MS patients needs to factor in comorbid de-
pression and fatigue. Particularly, cognitive tests that
rely predominantly on processing speed may be vulner-
able to bias.
Fatigue and sleep disorders
The Epworth Sleepiness Scale (ESS) is a screening
tool that assesses sleepiness [22], but normal values
do not entirely rule out sleep disorders as these are
not always associated with sleepiness. Two polysom-
nographic studies investigating sleep disorders and fa-
tigue in consecutive MS patients have demonstrated a
significant relationship between fatigue and sleep dis-
orders [17, 68]. Interestingly, a significant association
existed between the presence of a sleep disorder and
MFIS and FSS values, but not between fatigue and
ESS values [17]. Both former groups monitored their
individual study subjects in an open follow-up study
and found that sleep medical treatment significantly
reduced fatigue; however, prospective controlled stud-
ies are lacking [69, 70]. In the study by Veauthier et
al., 49 out of 66 consecutive MS patients suffered
from sleep disorders as confirmed by polysomnogra-
phy [17]. The most common sleep disorders diag-
nosed in MS are obstructive sleep apnea (OSA),
insomnia, periodic limb movement disorder (PLMD),
restless legs syndrome (RLS), and sleep disruption
due to nocturia.
Well-established diagnostic criteria that can accurately
compare the prevalence of insomnia in the general popu-
lation compared to MS patients are lacking. A discussion
of insomnia in MS is provided in a recent review [2]. Im-
portantly, in the clinical setting, over-the-counter drugs
against insomnia (for example, products that contain di-
phenhydramine) can lead to next-day fatigue [71–73].
As mentioned above, prevalence of RLS is four times
higher in MS compared to the general population. MS
patients with RLS also show higher EDSS values and sig-
nificantly reduced cervical cord fractional anisotropy in
MRI examinations compared with MS patients without
RLS—indicating a more pronounced cervical cord dam-
age in MS patients with RLS [32, 33, 74, 75]. MS pa-
tients with more than ten periodic leg movements
(PLMs) per hour of REM sleep showed a significantly
higher disability measured by the EDSS [33].
With regards to MS and sleep apnea, it is currently
unknown whether MS lesions can cause sleep apnea and
whether the prevalence of sleep apnea is increased in
MS [2, 76]. In the general population, sleep apnea can
cause depression, and conversely, the treatment of sleep
apnea by continuous positive airway therapy (CPAP) can
be effective in the treatment of depression [77, 78]. This
is especially important given the link between fatigue
and depression in MS [19, 79]. Studies investigating the
impact of treatment for nocturia in MS fatigue are lack-
ing, but only half of MS patients with moderate to se-
vere overactive bladder symptoms are treated with an
anticholinergic medication [80].
As polysomnographic assessment is time consuming,
defining which patients should undergo the test is crit-
ical. In order to develop a screening instrument, we per-
formed a retrospective receiver operating characteristic
(ROC) analysis of the investigated MS patients investi-
gated by polysomnography (PSG)—using the MFIS for
daytime dysfunction and the Pittsburgh Sleep Quality
Index (PSQI) for sleep disturbances [81, 82]. By jointly
applying the MFIS cutoff of 34 and the PSQI cutoff of 5
(either MFIS > 34 or PSQI > 5), we achieved a sensitivity
of 89.8% for sleep disorders (specificity 58.8%, positive
predictive value 86.3%, negative predictive value 66.7%).
Structural and functional MRI correlates
As structural and diffuse brain damage are detectable
from the earliest disease stages, multiple studies have
attempted to relate fatigue severity assessed by different
questionnaires and sometimes in conjunction with
cognitive dysfunction to various neuroimaging findings
acquired using structural, functional, and metabolic
imaging modalities [83–88]. For example, a magnetic
resonance spectroscopy study has indicated decreased
N-acetylaspartate-creatine ratios (NAA/Cr) as a marker
of axonal metabolic integrity with increasing fatigue
scores, suggesting diffuse and widespread axonal dys-
function as a contributor to fatigue in MS [89]. Struc-
tural imaging studies focusing on the quantification of
atrophy have reported an association of fatigue severity
with atrophy in the thalamus and a number of different
cortical gray matter regions (superior frontal and inferior
parietal gyrus, parietal lobe) in patients with relapsing-
remitting MS [90, 91]. Yaldizli et al. found an association
between callosal atrophy and fatigue and cognitive per-
formance in a large cohort of MS patients with various
disease courses [92], and Nygaard et al. reported a rela-
tion between regionally smaller cortical surface areas
and volumes and higher depression and fatigue scores in
relapsing-remitting MS patients [93]. Although Gobbi et
al. did not find an association between white matter at-
rophy and lesion distribution [94], a previous study by
Sepulcre et al. suggested a correlation between T2 lesion
load and fatigue severity and between fatigue scores and
gray matter atrophy in frontal regions [95]. Damasceno
et al. found an association between fatigue severity and
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atrophy in various cortical and gray matter regions; how-
ever, after controlling for disability and depression, only
caudate and accumbens volumes remained statistically
significant (interestingly, the nucleus accumbens is an
important mesolimbic structure involved in motivational
and reward processes) [96]. Caudate and basal ganglia
were also identified as regions related to clinical fatigue
by other imaging modalities. A positron emission tom-
ography study by Roelcke et al. found reduced glucose
metabolism in the frontal cortex and basal ganglia in MS
patients with fatigue [97], and in a resting-state fMRI
study, Finke et al. showed that fatigue severity was nega-
tively correlated with functional connectivity of the basal
ganglia with the medial prefrontal cortex, precuneus,
and posterior cingulate cortex [98]. These connectivity
changes suggest—in line with the above mentioned
study by Damasceno et al. [96]—that impairment of
both motor and non-motor functions of the basal gan-
glia, which also include reward processing and motiv-
ation, is involved in the pathophysiology of fatigue in
MS. Another fMRI study applying a motor task by Rocca
et al. found decreased activation of various frontal and
temporal cortical regions and—importantly—the basal
ganglia in MS patients with fatigue, versus MS patients
without fatigue and healthy controls. The authors inter-
preted this as a maladaptation of motor network recruit-
ment and a central contributor to fatigue [99].
Although these and other imaging studies provide in-
teresting data on imaging correlates of fatigue and
underscore that dopaminergic structures like the basal
ganglia may be significantly related to the perception of
fatigue, they merely describe statistical correlations or
associations and do not shed light on causality. More-
over, comparability between studies is limited by the het-
erogeneity of the applied imaging modalities, the clinical
cohorts assessed, and the fatigue questionnaires used,
which likely at least in part accounts for the discrepan-
cies between study findings. Moreover, in future studies,
sleep disorders as a major cause for secondary fatigue
and as an important confounder should be ruled out by
polysomnography prior to study enrollment.
Inflammation and neuroendocrine abnormalities
One intriguing observation from animal models and ex-
perimental studies in humans is that cytokines and other
inflammatory stimuli can induce sickness behavior symp-
toms, including anorexia, hypoactivity, and hyperthermia,
that resemble some aspects of fatigue [100–102]. This so-
called sickness behavior has therefore been proposed as a
pathobiological model of fatigue in the context of inflam-
matory disorders such as MS [103]. However, clinical
studies applying this model in the specific context of MS
have yielded mixed results. Circulating levels of several in-
flammatory markers such as interleukin-2 (IL-2),
neopterin, ICAM-1 (intercellular adhesion molecule 1),
and C-reactive protein (CRP) were not correlated with
fatigue [104, 105]. In contrast, two studies examining
proinflammatory cytokines such as TNFα (tumor ne-
crosis factor alpha) (but not interferon-γ (IFNγ))
mRNA in lymphocytes [106] and TNFα and IFNγ pro-
tein production after in vitro stimulation [107] reported
positive correlations with fatigue. A study subsequent
to the latter also found increased intracellular in vitro
production of IFNγ that correlated fatigue [108]. These
cytokines did not yield significant associations with fa-
tigue scores in a more comprehensive serum cytokine
screen, which however suggested an association of fa-
tigue with interleukin-6 (IL-6) [109].
Beyond inflammatory markers, several studies have also
investigated the relationship between alterations in neuro-
endocrine systems, such as the hypothalamo-pituitary-
adrenal (HPA) axis, and MS-related fatigue. Again, study
findings were mixed. Whereas Gottschalk et al. found a
higher activity of the HPA axis in MS fatigue patients, as
evidenced by significantly increased adrenocorticotropin
(ACTH) concentrations, Heesen et al. reported that HPA-
axis feedback-regulation (as determined by the Dex-CRH
suppression test) axis activity was not related to fatigue
[107, 110]. Resting levels of cortisol (as measured by a sin-
gle midday blood sample) were also not associated with
fatigue in another study [111]. More recently, one study
reported an association of fatigue in relapsing-remitting
MS (RR-MS) with lower waking cortisol levels and an in-
creased response to awakening (cortisol awakening re-
sponse (CAR)), indicating that cortisol could play a role in
the perception of fatigue [112], but two studies assessing
the circadian slope of cortisol secretion did not find an as-
sociation with MS fatigue [108, 112].
In summary, while the role of inflammation in the
pathobiology of “fatigue-like” symptoms is well supported
by animal models and experimental studies in humans, no
individual immune or neuroendocrine markers have con-
sistently been associated with fatigue in MS. Some of this
might be due to the large heterogeneity of markers, chal-
lenge paradigms, and the definition of fatigue used in each
particular study. Moreover, in light of the abovementioned
high prevalence of sleep disorders in MS fatigue, future
studies investigating the neuroinflammatory and neuroen-
docrine aspects of MS-associated fatigue should take care
to apply polysomnography to exclude possible bias result-
ing from sleep disorders as confounder.
Methodical limitations and further research direction
Diversity between study cohorts (e.g., with or without sec-
ondary progression, level of disability, treatment naïve or
not) is a long-standing problem hampering definitive in-
terpretation of research into MS as a whole. The investiga-
tion of MS-related fatigue is additionally complicated by a
Veauthier et al. The EPMA Journal  (2016) 7:25 Page 6 of 16
lack of standardization between fatigue scales and, even
more seriously, by the fact that the potential confounders
(sleep disorders and drug side effects) are not excluded as
a matter of course. Definitively identifying mutual rela-
tionships between distinct parameters (imaging or depres-
sion or disease course or cognitive dysfunction or sleep
disorders or inflammation and fatigue) across different
studies becomes neigh on impossible. To date, not one
study into MS-related fatigue has examined all parameters
and excluded all known confounders. Such a task would
be even more difficult in the context of urgently needed
large multicenter studies.
Treatment of MS fatigue
Immune therapy and fatigue
The same methodical limitations apply to the published
data on the impact of MS treatment on fatigue. The lack
of studies investigating the influence of existing MS
therapies on MS fatigue as a primary endpoint and the
influence of other confounders, such as age, disease
course and duration, questionnaires used, medication,
comorbid disorders (e.g., depression), and the lack of a
control group in most studies, have hampered insight
into the effect of disease-modifying therapies on MS-
related fatigue. However, a number of studies suggest
that beta interferons and glatiramer acetate (GA) reduce
fatigue (with GA treatment potentially more effective)
[113–116]. The effect of natalizumab on fatigue varied
between studies [117, 118]. Whereas Penner et al. found
that fatigue levels remained constant or decreased in the
majority of patients after 1 year of natalizumab treat-
ment, Kunkel et al. found no significant changes, al-
though this may have been due to the study’s small
cohort size [117, 118].
Some limited results show that fingolimod might im-
prove fatigue after changing from beta interferon to fin-
golimod (but not from GA) [119, 120]. However, no
evidence exists that teriflunomide, dimethyl fumarate, or
alemtuzumab improve fatigue [121–123]. In fact, one
study identified fatigue as a side effect of dimethyl fu-
marate treatment [122].
Management strategies recommended by the MS Council
As fatigue is not specific or unique to MS [124–126], in
1998, the MS Council for Clinical Practice Guidelines
recommended performing blood tests and evaluating co-
morbid medical conditions, iatrogenic factors, depres-
sion or psychological distress, sleep disturbances, and,
where applicable, as next diagnostic step sleep studies
(polysomnography and multiple sclerosis latency test)
[9]. Chronic obstructive pulmonary disease (COPD)
should also be excluded [9]. After ruling out or address-
ing any comorbid medical conditions, drug therapy, (aer-
obic) exercise, and, among others, self-management
strategies were recommended. Self-management strategies
included activities such as cessation of smoking, modifying
dietary habits, optimizing time management, adjusting ac-
tivity levels, taking naps, consumption of cool beverages,
cool showers and baths for heat intolerance, exercise pro-
grams, or engaging in relaxation exercises.
Drug therapy
One recently published trial (alfacalcidol versus placebo)
showed a significant reduction of fatigue under therapy
with alfacalcidol (an active vitamin D3 metabolite requir-
ing activation in the liver) [127]. Further studies are
needed in order to confirm this effect. Apart from vitamin
D, in recent studies, modafinil, amantadine, carnitine, or
pemoline [16, 128–136] have generally not been found to
be effective in treating MS-related fatigue. Our review of
the literature found six meta-analyses of the randomized
controlled trials (modafinil, amantadine, carnitine, and
pemoline) [16, 128, 130, 131, 133–135, 137–140].
Whereas one meta-analysis investigating three studies
published before 1996 found a significant effect of aman-
tadine superior to placebo [141], five other meta-analyses
analyzing these three studies and further recent studies
did not report any significant effect of the investigated
drugs [129, 136, 142–144]. One study, however, did find a
significant improvement of fatigue under treatment with
carnitine compared to amantadine [140]. Aspirin was
found to be an effective treatment for fatigue in another
study [145], although this was countered by a subsequent
study comparing aspirin with amantadine treatment [130].
Motor fatigue and fampridine
4-Aminopyridine (dalfampridine, fampridine), a potas-
sium channel blocker, is approved by the US Food and
Drug Administration, Health Canada, and the European
Medicines Agency as a treatment for MS-related walking
ability [146]. Clinical trials have shown improvement in
walking speed compared to placebo (the percentage of
MS patients with an improvement in 6-min walk test of
>20% (45.1%) was significantly greater with dalfampri-
dine relative to placebo (14.3%)) [146, 147].
Furthermore, two studies showed that fampridine im-
proves MS fatigue as assessed using the visual analog scale
(VAS), the MFIS, and the FSS [148, 149]. Treatment with
fampridine should be stopped immediately in patients pre-
senting with hypersensitivity symptoms, such as swollen face,
mouth, lips, throat or tongue, reddening or itching of the
skin, chest tightness and breathing problems, and seizures
(up to 1 in 100 people). A number of other unpleasant but
harmless side effects exist, including urinary tract infection
(>10%) and dizziness, headache, sleep disturbances, and anx-
iety (<10%). Fampridine is contraindicated in patients with a
creatinine clearance lower than 80 ml/min, and therefore,
renal function should be monitored. Initial prescription
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should be limited to 2 weeks of therapy, which is the dur-
ation needed to assess clinical benefit. Extension of treatment
should be subject to improvement as assessed by a timed
walking test. If no improvement is observed at this point, the
fampridine treatment should be discontinued. Fampridine is
contraindicated during pregnancy.
Fatigue management interventions, rehabilitation
intervention and cognitive behavioral therapy
Rehabilitation (exercise or physical therapy, educa-
tional interventions such as mindfulness training, self-
management program, vestibular rehabilitation) and
cognitive behavioral therapy (CBT) are significantly
effective against MS-related fatigue [136, 150–153].
Moreover, internet-based CBT has been investigated
and could play a greater role in the future [154, 155].
A 2014 systematic review and meta-analysis by Asano
and Finlayson compared pharmacotherapy, exercise, and
educational interventions for MS-related fatigue [136],
suggesting that the eight reports of educational ap-
proaches yielded a significant overall effect with an effect
size of 0.54 (95% CI 0.30–0.77, p < 0.001). In particular,
the three trials that used CBT exhibited the largest effect
within the educational intervention subsection of the re-
view [154–156]. One additional trial has been published
since the above review combining CBT with energy con-
servation. Here, too, significantly reduced fatigue was
found (standardized effect size 0.54). A follow-up ana-
lysis found that some of the effects were maintained at
12 months post-trial [157].
Overall, strong evidence exists that educational inter-
ventions have a definitive moderate ability to reduce
MS-related fatigue. It should be noted that the studies
surveyed were generally combined elements of CBT,
mindfulness, skill training, and educational components.
Published evidence to date suggests that CBT-based in-
terventions are the most effective elements of a fatigue
management program (see Table 1). Finally, the settings
of these interventions also vary from group to one-on-
one sessions or from in-person to telephone or internet
intervention. The available trials (see Table 1) suggest
that individual intervention might yield larger effects
than group interventions; however, this has not been for-
mally studied to date. For the time being, the setting
used should be based on the resources available and the
specific needs and requirements of the patient popula-
tion. Remote access options like telephone or Internet
sessions might be particularly suitable for patients with
mobility problems or patients in rural areas.
Treatment of underlying sleep disorders
The first step to addressing MS-related fatigue is diagnos-
ing and treating any underlying sleep disorders. Two stud-
ies of sleep disorders and fatigue in consecutive MS
patients have demonstrated a significant relationship be-
tween fatigue and sleep disorders [17, 68]. In the study by
Veauthier et al., 96% of fatigued MS patients were suffering
from a sleep disorder [17]. Sleep disorders are frequent in
MS and have been significantly associated with higher
MFIS values. MS patients suffering from sleep disorders
show increased MFIS values compared to MS patients who
are not suffering from sleep disorders (SD ±42.8 versus
±20.5, p < 0.001) [17]. Besides depression and disability,
sleep disturbances decrease health-related quality of life
(HRQoL) [158, 159]. Although OSA is a prevalent patho-
logical condition and represents an increased risk for car-
diovascular diseases, a majority of patients remain
undiagnosed [160, 161]. In particular, MS patients suffering
from comorbid obstructive sleep apnea (OSA) or insomnia
showed significantly decreased HRQoL for the “sleep” area
(sleep subscale). But furthermore, OSA and insomnia pa-
tients show increased values in the “energy” and “emo-
tional” subscales as well indicating that sleep disorders lead
to impaired daytime functioning (and in OSA patients also
for “physical abilities”) [158].
The most important sleep disorders in this context
are OSA, insomnia, periodic limb movement disorder
(PLMD), restless legs syndrome (RLS), and nocturia
Table 1 Trials using educational interventions in MS-related fatigue
Sample size Intervention Effect size (according to meta-analysis
by Asano and Finlayson)
Mohr et al. 2003 [156] 60 CBT (individual sessions) 0.80 (0.19–1.42)
Mathiowetz et al. 2005 [188] 169 Fatigue management program (energy conservation course)
(group sessions)
0.42 (0.08–0.76)
Kos et al. 2007 [189] 51 Multidisciplinary fatigue management program (group sessions) −0.16 (−0.72 to 0.38)
Van Kessel et al. 2008 [155] 72 CBT (individual and phone sessions) 0.99 (0.50–1.48)
Grossman et al. 2010 [150] 150 Mindfulness (group sessions) 0.42 (0.09–0.74)
Hugos et al. 2010 [190] 30 Fatigue management program (group sessions) 0.43 (−0.29 to 1.57)
Finlayson et al. 2011 [191] 190 Fatigue management program (phone sessions) 0.53 (0.19–0.86)
Moss-Morris et al. 2012 [154] 40 CBT (online + phone sessions) 1.11 (0.43–1.78)
Thomas et al. 2013 [157] 164 CBT + energy effectiveness training (group) 0.54 (not included in meta-analysis)
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[2]. In two open follow-up studies, the treatment of
an underlying sleep disorder (continuous positive air-
way pressure (CPAP) for OSA, drug therapy and CBT
for insomnia, and drug therapy for RLS and PLMD)
significantly reduced fatigue, but prospective con-
trolled studies are lacking [69, 70].
Many studies investigating fatigue have used the
Epworth Sleepiness Scale (ESS) as a screening tool for
sleep disorders [16, 22, 162]. That is not entirely correct.
The ESS is a diagnostic instrument for sleepiness, not fa-
tigue, and is especially recommended in the context of
hypersomnia, OSA, and narcolepsy. A part of patients suf-
fering from sleep disorders feel sleepy, but a significant
proportion does not feel sleepy but rather fatigued. There-
fore, the ESS is not a suitable questionnaire for all sleep
disorders. In insomnia and other sleep disorders like RLS
or PLMD, specific questionnaires are recommended: the
Pittsburgh Sleep Quality Index (PSQI) or the Insomnia Se-
verity Index (ISI) for insomnia and the RLS Diagnostic
Index (RLS-DI) for RLS [81, 163, 164]. These question-
naires cannot reflect the complex symptoms of sleep dis-
orders and are only screening tools—clinical interview by
a sleep expert and objective testing (polysomnography)
are the gold standard of sleep medical diagnosis.
The Berlin Treatment Algorithm
It is one thing to recommend the treatment of under-
lying sleep disorders in this issue in general, but an-
other to say which patient has to be sent to the sleep
specialist or sleep laboratory. Because of the complex-
ity of the issue and due to the fact that clinicians
need some practical instructions, the discussion of the
different treatment options does not replace the need
for a practical guide with specific procedures and
measures. We would like to take the opportunity to
introduce our Berlin Treatment Algorithm of MS fa-
tigue, which we developed in the last years. Figure 2
outlines the treatment algorithm.
Fig. 2 The Berlin Treatment Algorithm. Please note: Restless legs syndrome can be diagnosed on the basis of the following four minimal criteria:
an urge to move the legs (usually accompanied by uncomfortable sensations), which begin or worsen during rest and are relieved by movement
predominantly in the evening or night. Depression can be diagnosed by structured interviews. Self-report scales (e.g., Beck Depression Inventory
(BDI)) can be useful to screen for depression. Abbreviations: MFIS Modified Fatigue Impact Scale, PSQI Pittsburgh Sleep Quality Index, ESS Epworth
Sleepiness Scale, COPD chronic obstructive pulmonary disease, SSRIs selective serotonin reuptake inhibitors, CBT cognitive behavioral therapy
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Phase A: basic recommendations
The Berlin Treatment Algorithm follows the recommen-
dations of the MS Council for Clinical Practice Guidelines
as a first step: As an initial step, blood tests should be per-
formed to rule out anemia, thyroid dysfunction, renal and
hepatic insufficiency, vitamin D deficiency, and infections.
In cases of possible COPD (due to smoking), pulmonary
function tests and blood gas analysis are also recom-
mended. At this stage, medical history questionnaires
should also address a patient’s use of sedative drugs, in-
cluding over-the-counter medicines, which might worsen
fatigue. Weaning or reducing patient consumption of such
drugs would be the next necessary step. If the patient has
recently been suffering from fatigue, a neurological exam-
ination should be performed to rule out relapse or disease
progression and an MRI should be performed in order to
assess radiographic disease activity [165]. Once the above
confounders have either been addressed or excluded, the
patient should fill out the MFIS and the PSQI. Then, all
patients with higher MFIS values >34 and/or PSQI values
>5 should enter the next phase.
Phase B: specific therapy
At this stage, possible causes of fatigue should be identified
by a diagnostic interview. The latter should include ques-
tions about both current and past fatigue symptoms and
focus mainly on determining whether nocturia, depression,
and sleep disorders (OSA, insomnia, RLS, behaviorally in-
duced insufficient sleep syndrome (BIISS)) play a role [21].
Restless legs syndrome RLS is defined by an urge to
move the legs, usually accompanied by uncomfortable and
unpleasant sensations in the legs, which is partially or to-
tally relieved by movement. The discomfort begins or
worsens during periods of rest or inactivity and in the even-
ing or at night on condition that its occurrence is not solely
accounted for as symptoms primary to another medical or
a behavioral condition [166]. RLS is often misdiagnosed in
MS patients, and RLS-associated symptoms are often mis-
interpreted as spasticity in more disabled patients.
Treatment of RLS symptoms consists of iron supple-
mentation, if ferritin serum levels are lower than 75 mcg/l,
and dopaminergic drugs [167–169]. Pregabalin is effective
against RLS symptoms as well, but it is not approved in
some countries for the treatment of RLS [170].
The questionnaire Restless Legs Syndrome Diagnostic
Index (RLS-DI) is used as a screening tool; however, this
cannot replace a diagnostic interview by a sleep expert.
The International RLS Study Group (IRLSSG) rating
scale should be used for the assessment of the response
to therapy [164, 171].
Insomnia Whereas impaired sleep maintenance can be
an unspecific symptom of sleep disorders in general
(OSA, insomnia, and others), delayed sleep onset with
prolonged sleep latencies before falling asleep is a clear
indication for sleep-onset insomnia. Such patients can
be treated with sleep restriction therapy and sleep hy-
giene education, relaxing routine within an hour before
bedtime, regular exercise, avoiding daytime napping, and
late heavy meals [172, 173]. Sleep restriction is an easy
and very efficacious therapy against sleep-onset insomnia
[174]. Prescription and over-the-counter drug therapies in-
clude short-acting non-benzodiazepine sedative-hypnotic
agents; ramelteon, a melatonin receptor agonist; trazodone;
antidepressants; and sedating antihistamines [175]. Thyroid
hyperfunction should be ruled out, and coffee should be
avoided (in particular, in the afternoon and evening).
Behaviorally induced insufficient sleep syndrome
Sleepiness may be caused by behaviorally induced insuf-
ficient sleep syndrome (BIISS), which can only be diag-
nosed by a detailed medical history [21]. Doctors should
not only ask about sleep problems, but also about time
spent in bed (currently and in the past, on workdays,
and at weekends) and about fatigue severity during
workdays and during holidays. Longer sleep times on
the weekend or during holidays point to BIISS. Sleep
diaries or actigraphy may be helpful. In severe cases, re-
ferral to a sleep expert can be necessary [167].
Obstructive sleep apnea If patients suffer from sleepi-
ness (especially in case of ESS values ≥10), they should
be referred to a sleep specialist or admitted to a sleep la-
boratory, for assessment of possible narcolepsy, hyper-
somnia, or (more frequently) obstructive sleep apnea;
symptoms of the latter include snoring, non-restorative
sleep, morning headaches, dry mouth, nocturnal gasping
or apnea, cardiovascular diseases, increased neck cir-
cumference, obesity, and a family history of OSA [20].
Nocturia Patients with nocturia (≥2 times per night)
should be referred to a urologist, and a treatment with
an anticholinergic or alpha-blocker should be considered
[80, 176].
Depression Depression should be diagnosed using
current criteria (e.g., Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition (DSM-V) [177] or the
International Statistical Classification of Diseases and
Related Health Problems (ICD-10) [178]). This should
ideally be done using standardized tools such as struc-
tured diagnostic interviews by experienced clinicians.
Self-report scales such as the Beck Depression Inventory
(BDI-II) can be used as a screening tool to identify pa-
tients requiring further diagnostic work-up. Recom-
mended cutoffs for the general population are BDI
values >13 in treated depressed patients and BDI-II >21
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in treatment naïve patients [179]. For MS patients,
these cutoffs might need to be adjusted to optimize
sensitivity and specificity, depending on the clinical
context [13, 180]. As a brief screening tool, the two-
item approach by Mohr and colleagues has been rec-
ommended by the American Academy of Neurology
(AAN) task force [156, 181].
In cases of depression, the treatment should include
tailored treatment algorithms and multimodal ap-
proaches and a comprehensive treatment should include
primarily psychotherapy and optionally pharmacother-
apy [182]. Selective serotonin reuptake inhibitors (SSRIs)
are generally considered to be an effective and well-
tolerated first-line treatment [183]. The guidelines pub-
lished by the AAN did not recommend antidepressant
pharmacotherapy for depression in MS due to a lack of
conclusive evidence; however, more recently, a meta-
analysis reported overall beneficial effects [181, 184, 185].
Cognitive behavioral therapy and mindfulness-based inter-
ventions have shown efficacy in improving depressive dis-
orders in MS [181, 185].
Phase C: drug therapy
Fampridine prescribed for walking ability may be effect-
ive against fatigue as well, and one recent published ran-
domized controlled trial (RCT) showed a substantial
improvement of fatigue under therapy with vitamin D
(alfacalcidol, if blood calcium levels are not higher than
10.5 mg/dl)—but despite the substantial psychosocial
burden of MS-related fatigue, there are no pharmaco-
logical treatments formally approved by regulatory au-
thorities [127, 129, 136, 149, 186]. Despite poor
evidence, individual attempts to improve fatigue with
modafinil, amantadine or carnitine may be undertaken.
Phase D: intensified sleep medical therapy
Patients without improvement in fatigue following measures
undertaken during the preceding phases should be admitted
to a sleep laboratory in order to diagnose or exclude other
underlying sleep disorders according to the ICSD-3 (Inter-
national Classification of Sleep Disorders, Third Edition),
which cannot be diagnosed by the diagnostic interview and
questionnaires alone (for example, sleep-related breathing
disorders including central apnea, obstructive sleep apnea,
obesity hypoventilation syndrome, periodic limb movement
disorder, parasomnia, insomnia) [20]. In some cases, a speci-
fied sleep medical treatment (continuous positive airway
pressure (CPAP) or drug therapy) can be started and fatigue
may improve.
Phase E: rehabilitation and cognitive behavioral therapy
If fatigue persists, patients should participate in exercise
therapy (aerobic exercise or resistance training) at least
once a week or CBT [9, 183]. This can be undertaken
individually or as part of a group therapy and would be
facilitated by tertiary MS centers collaborating with
physical therapists or physical medicine and rehabilita-
tion specialists in order to develop interned-based and
cost-effective interventions.
Outlook
In the future, novel approaches such as smartphone–
based applications might play a role in measuring per-
formance and patient-reported outcomes and improving
fatigue by self-management strategies [187].
Conclusions
The treatment of MS-related fatigue remains a challen-
ging task, particularly due to the lack of a proven pharma-
cological therapy. However, many other therapeutic
strategies have been shown to be effective in the treatment
of MS-related fatigue. Therefore, a comprehensive ap-
proach including self-management strategies, rehabilita-
tion, CBT, and the treatment of underlying sleep disorders
and potentially other comorbidities is reasonable. The aim
of the algorithm presented is to provide the treating physi-
cians with a practical guide facilitating diagnosis and treat-
ment of MS fatigue in individual patients.
Expert recommendation
Personalized medicine is a promising new therapeutic
strategy in order to treat MS-related fatigue. The treatment
of fatigue should be tailored to the MS patients—taking
into account comorbid disorders such as RLS, insomnia,
depression, history of snoring and sleep apnea, nocturia,
and sleep deprivation as well as side effects of the medica-
tion. Patients with high MFIS or PSQI values indicating a
high risk of sleep disorders should be investigated by poly-
graphy or polysomnography.
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